 |
|
|
| |
Superior Efficacy of Dolutegravir (DTG) Plus
2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared With Lopinavir/Ritonavir (LPV/RTV) Plus
2 NRTIs in Second-Line Treatment: Interim Data From the DAWNING Study
|
| |
| |
Reported by Jules Levin
9th IAS Conference on HIV Science, July 23-26 2017, Paris, France
Michael Aboud,1 Richard Kaplan,2 Johannes Lombaard,3 Fujie Zhang,4
Jose Hidalgo,5 Elmira Mamedova,6 Marcelo Losso,7 Ploenchan Chetchotisakd,8 Jorg Sievers,1 Dannae Brown,9 Judy Hopking,10 Mark Underwood,11
Maria Claudia Nascimento,1 Martin Gartland,11 Kimberly Smith11
1ViiV Healthcare, Brentford, UK; 2Desmond Tutu HIV Foundation, Cape Town, South Africa; 3Josha Research, Bloemfontein, South Africa; 4Beijing Ditan Hospital, Beijing, China; 5VIA LIBRE, Lima, Peru; 6Kiev AIDS Centre, Kiev, Ukraine; 7Hospital J M Ramos Mejia, Buenos Aires, Argentina; 8Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand; 9ViiV Healthcare, Abbotsford, Australia; 10GlaxoSmithKline, Stockley Park, UK; 11ViiV Healthcare, Research Triangle Park, NC, USA
|
| |
|
|
|
|
|
